Leading drug manufacturers are actively lobbying President Trump to introduce a phased approach to tariffs on imported pharmaceutical products. They aim to minimize the immediate impact of these charges and allow ample time to adjust manufacturing operations. This strategy reflects the industry’s desire to maintain stability while navigating the trade landscape. Industry insiders believe that phased tariffs could soften the blow on consumers and businesses alike. Continuous dialogue between the pharmaceutical sector and the government will play a vital role in shaping future policies. The outcome of these discussions may significantly influence the sector’s trajectory moving forward.